Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on November 4, 2022. The report serves to announce the Company's financial results for the quarter ended September 30, 2022. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol OCUP.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No material changes or comparative financial data are disclosed within the text of this filing. The document solely references the issuance of the press release regarding the third-quarter results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under General Instruction B.2 of Form 8-K. It states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. Consequently, no specific guidance, management commentary, or risk factors are detailed in this summary document.
Investor Verification Checklist
- Verify the correct registrant name is Ocuphire Pharma, Inc. (OCUP), not Opus Genetics, Inc.
- Review Exhibit 99.1 (the Press Release dated November 4, 2022) for actual financial figures, as they are absent from the 8-K text.
- Confirm the reporting period is the quarter ended September 30, 2022.
- Note that the financial data in the referenced press release is not deemed "filed" under the Exchange Act.